Table 4.
Median survival time, restricted mean survival time, and restricted mean lost time analysis of onset of analgesia using the double-stopwatch method.
| Pain relief (event) time | Perceptible pain relief | Meaningful pain relief | |||
|---|---|---|---|---|---|
| TBF | Placebo | TBF | Placebo | ||
| Symptom resolved (n = 116) | 115 | 12 | 111 | 2 | |
| Median survival time | 60 | NE | 180 | NE | |
| Restricted mean survival time (RMST ± SE) | 68.5 ± 4.562 | 340.7 ± 6.076 | 191.6 ± 7.581 | 358.1 ± 1.804 | |
| 95% CL (LL–UL) | 59.5–77.4 | 328.8–352.6 | 176.7–206.4 | 354.6–361.6 | |
| RMST difference ± SE (placebo-TBF) (P-value) | 272.3 ± 7.598 (P < .0001) | 166.6 ± 7.793 (P < .0001) | |||
| 95% CL (LL–UL) | 257.4–287.1 | 151.3–181.8 | |||
| RMST ratio ± SE (placebo/TBF) | 4.98 ± 0.069 (P < .0001) | 1.87 ± 0.04 (P < .0001) | |||
| 95% CL (LL–UL) | 4.35–5.7 | 1.73–2.02 | |||
| Restricted mean lost time (RMLT ± SE) | 291.5 ± 4.562 | 19.3 ± 6.076 | 168.4 ± 7.581 | 1.9 ± 1.804 | |
| 95% CL (LL–UL) | 282.6–300.5 | 7.4–31.2 | 153.6–183.3 | −1.6 to 5.4 | |
| RMLT ratio (placebo/TBF) ± SE | 0.07 ± 0.315 (P < .0001) | 0.01 ± 0.952 (P < .0001) | |||
| 95% CL (LL–UL) | 0.04–0.12 | 0–0.07 | |||
Total available time = 360 min.
NE = not estimable; RMLT = restricted mean survival time lost; RMST = restricted mean survival time; TBF = turmeric-boswellia formulation.